Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) have received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $19.33 for the company, according to Zacks. Zacks has also given Aileron Therapeutics an industry rank of 109 out of 265 based on the ratings given to related companies.

A number of research analysts have recently commented on ALRN shares. Jefferies Group LLC started coverage on Aileron Therapeutics in a research note on Monday, July 24th. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity started coverage on Aileron Therapeutics in a research note on Monday, July 24th. They issued a “buy” rating and a $19.00 target price for the company. Bank of America Corp started coverage on Aileron Therapeutics in a research note on Monday, July 24th. They issued a “buy” rating and a $19.00 target price for the company. Finally, William Blair started coverage on Aileron Therapeutics in a research note on Monday, July 24th. They issued an “outperform” rating for the company.

Aileron Therapeutics (NASDAQ:ALRN) traded down 0.74% during midday trading on Tuesday, hitting $12.04. The stock had a trading volume of 14,946 shares. The company’s market cap is $177.17 million. Aileron Therapeutics has a 12 month low of $10.37 and a 12 month high of $15.48. The firm’s 50-day moving average price is $13.21 and its 200 day moving average price is $12.84.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALRN. Candriam Luxembourg S.C.A. bought a new position in Aileron Therapeutics during the 2nd quarter valued at approximately $1,673,000. Jennison Associates LLC bought a new position in Aileron Therapeutics during the 2nd quarter valued at approximately $2,788,000. Neuberger Berman Group LLC bought a new position in Aileron Therapeutics during the 2nd quarter valued at approximately $279,000. Sphera Funds Management LTD. bought a new position in Aileron Therapeutics during the 2nd quarter valued at approximately $1,394,000. Finally, Laurion Capital Management LP bought a new position in Aileron Therapeutics during the 2nd quarter valued at approximately $335,000. Institutional investors own 12.33% of the company’s stock.

WARNING: “Aileron Therapeutics, Inc. (ALRN) Given $19.33 Consensus Target Price by Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/31/aileron-therapeutics-inc-alrn-given-19-33-consensus-target-price-by-analysts.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.